Go Pro
NASDAQ:REVB

Revelation Biosciences Q2 2026 Earnings Report

Revelation Biosciences logo
$1.08 +0.05 (+4.33%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revelation Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.83
Beat/Miss
N/A
One Year Ago EPS
N/A

Revelation Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Revelation Biosciences Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 7, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Revelation Biosciences Earnings Headlines

REVB Poised for Big Year
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
REVB Comes to Agreement with FDA
See More Revelation Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email.

About Revelation Biosciences

Revelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

View Revelation Biosciences Profile